Oral Squamous Cell Carcinoma Clinical Trial
Official title:
Detection of Oral and Throat Cancers Using Saliva Metatranscriptomic Analysis
To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.
This is an observational study evaluating the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic. A total of 475 participants will be recruited, including 4 different cohorts: 1) cancer free patients, 2) patients with Oral Potentially Malignant Disease (OPMD), 3) patients with Oral Squamous Cell Carcinoma (OSCC), and 4) patients with OroPharyngeal Cancer (OPC). OSCC and OPC participants will be recruited from secondary care facilities, OPMD and cancer free participants will be recruited from primary care facilities. Participants will complete health questionnaires and collect saliva samples using at home/ in clinic kits provided by Viome. The duration of study participation will be 1 clinic visit for cancer free participants, and up to 1 year for those with OSCC/OPC/OPMD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04543266 -
Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
|
||
| Recruiting |
NCT05024383 -
Dissecting the Heterogeneity of Oral Cancer Pain
|
N/A | |
| Recruiting |
NCT06031337 -
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
|
||
| Not yet recruiting |
NCT06174428 -
Validity of Viome's Oral/Throat Cancer Test
|
||
| Recruiting |
NCT05098119 -
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
|
Phase 2 | |
| Recruiting |
NCT05069857 -
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
|
Phase 2 | |
| Not yet recruiting |
NCT03619304 -
Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line
|
N/A | |
| Active, not recruiting |
NCT01772706 -
Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer
|
N/A | |
| Recruiting |
NCT05893888 -
Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05125055 -
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06055868 -
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
|
||
| Not yet recruiting |
NCT06130007 -
A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma.
|
Phase 2 | |
| Recruiting |
NCT05798793 -
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
|
Phase 3 | |
| Recruiting |
NCT02739204 -
Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT05708209 -
The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
|
||
| Recruiting |
NCT05862168 -
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
|
Phase 2 | |
| Recruiting |
NCT05902455 -
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
|
||
| Not yet recruiting |
NCT05803915 -
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
|
Phase 2 | |
| Recruiting |
NCT05791149 -
Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity
|
N/A | |
| Active, not recruiting |
NCT04649476 -
Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma
|
Phase 2 |